Home/Pipeline/UltraMIST® Therapy System

UltraMIST® Therapy System

Chronic, Non-Healing Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcers)

CommercialFDA 510(k) Cleared

Key Facts

Indication
Chronic, Non-Healing Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcers)
Phase
Commercial
Status
FDA 510(k) Cleared
Company

About Sanuwave

Sanuwave is a commercial-stage medical device company focused on shifting the standard of care for chronic wounds through its proprietary non-contact, low-frequency ultrasound (NCLFU) technology. Its flagship UltraMIST® System, cleared by the FDA, is central to the company's 'Energy First™' protocol, aiming to jumpstart stalled healing, reduce pain, and improve patient outcomes. The company's strategy hinges on driving commercial adoption in the massive advanced wound care market while generating robust clinical and economic data to secure broader reimbursement and provider acceptance.

View full company profile

About Sanuwave

Sanuwave is a commercial-stage medical device company focused on shifting the standard of care for chronic wounds through its proprietary non-contact, low-frequency ultrasound (NCLFU) technology. Its flagship UltraMIST® System, cleared by the FDA, is central to the company's 'Energy First™' protocol, aiming to jumpstart stalled healing, reduce pain, and improve patient outcomes. The company's strategy hinges on driving commercial adoption in the massive advanced wound care market while generating robust clinical and economic data to secure broader reimbursement and provider acceptance.

View full company profile